Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01975545|
Recruitment Status : Unknown
Verified March 2014 by Claudia Butrón Téllez Girón, Universidad Autonoma de San Luis Potosí.
Recruitment status was: Active, not recruiting
First Posted : November 3, 2013
Last Update Posted : March 7, 2014
|Condition or disease||Intervention/treatment||Phase|
|Down Syndrome||Drug: Fluor varnish Drug: Fluor varnish with nanoparticles||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Efficacy of the Addition of Silver Nanoparticles to a Fluor Varnish in the Remineralization of Temporary Teeth in Patients With Trisomy 21. Randomized Clinical Trial.|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||April 2014|
|Estimated Study Completion Date :||May 2014|
Active Comparator: Fluor varnish
Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
Drug: Fluor varnish
Dental varnish will be applied to one anterior superior teeth in a random side.
Other Name: Fluor dental varnish
Experimental: Fluor varnish with nanoparticles
Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
Drug: Fluor varnish with nanoparticles
Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
Other Name: Fluor dental varnish with silver nanoparticles.
- Remineralization [ Time Frame: 3 months ]Remineralization status will be assessed through laser fluorescence of the tooth with a Diagnodent probe (Diagnodent, Kavo, Madrid, Spain)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01975545
|Universidad Autónoma de San Luis Potosí|
|San Luis Potosí, Mexico, 78210|
|Study Director:||Mauricio Pierdant-Pérez, Md, MSc||Universidad Autónoma de San Luis Potosí|